<DOC>
	<DOCNO>NCT01568866</DOCNO>
	<brief_summary>The primary objective study compare progression-free survival patient multiple myeloma relapse 1 3 prior therapy treat carfilzomib plus dexamethasone bortezomib plus dexamethasone .</brief_summary>
	<brief_title>Phase 3 Study With Carfilzomib Dexamethasone Versus Bortezomib Dexamethasone Relapsed Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Multiple myeloma relapse progress disease study entry . 2 . Patients must evaluable multiple myeloma , least one follow ( assess within 21 day prior randomization ) : Serum Mprotein ≥ 0.5 g/dL , Urine Mprotein ≥ 200 mg/24 hour , In patient without detectable serum urine Mprotein , serum free light chain ( SFLC ) &gt; 100 mg/L ( involved light chain ) abnormal serum kappa/lamda ratio , For immunoglobulin ( Ig ) A patient whose disease reliably measure serum quantitative immunoglobulin ( qIgA ) ≥ 750 mg/dL ( 0.75 g/dL ) . 3 . Patients must document least partial response ( PR ) least 1 line prior therapy . PR documentation base Investigator assessment . 4 . Received 1 , 3 prior treatment regimen line therapy multiple myeloma . ( Induction therapy follow stem cell transplant consolidation/maintenance therapy consider one line therapy ) . 5 . Prior therapy Velcade allow long patient least PR prior Velcade therapy , remove Velcade therapy due toxicity , least 6 month Velcade treatmentfree interval last dose receive first study treatment . ( Patients may receive maintenance therapy drug proteasome inhibitor class 6 month Velcade treatmentfree interval ) . 6 . Prior therapy carfilzomib allow long patient least PR prior carfilzomib therapy , remove carfilzomib therapy due toxicity , least 6month carfilzomib treatmentfree interval last dose receive first study treatment . ( Patients may receive maintenance therapy drug proteasome inhibitor class 6 month carfilzomib treatmentfree interval ) . The exception patient randomize previously randomize OnyxSponsored Phase 3 trial . 7 . Males females ≥ 18 year age . 8 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . 9 . Adequate hepatic function within 21 day prior randomization , bilirubin &lt; 1.5 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 time ULN . 10 . Left ventricular ejection fraction ( LVEF ) ≥ 40 % . 11 . Absolute neutrophil count ( ANC ) ≥ 1000/mm³ within 21 day prior randomization . Screening ANC independent growth factor support ≥ 1 week . 12 . Hemoglobin ≥ 8.0 g/dL within 21 day prior randomization . Use erythropoietic stimulating factor red blood cell ( RBC ) transfusion per institutional guideline allow , however recent RBC transfusion may do within 7 day prior obtain screen hemoglobin . 13 . Platelet count ≥ 50,000/mm³ ( ≥ 30,000/mm³ myeloma involvement bone marrow &gt; 50 % ) within 21 day prior randomization . Patients receive platelet transfusion least 1 week prior obtain screen platelet count . 14 . Calculated measured creatinine clearance ( CrCl ) ≥ 15 mL/min within 21 day prior randomization . Calculation base standard formula Cockcroft Gault : [ ( 140 Age ) x Mass ( kg ) / ( 72 x Creatinine mg/dL ) ] ; multiply result 0.85 female . 15 . Written inform consent accordance federal , local , institutional guideline . 16 . Female patient childbearing potential ( FCBP ) must negative serum pregnancy test within 21 day prior randomization agree use effective method contraception 3 month follow last dose drug ( frequent pregnancy test may conduct require per local regulation ) . FCBP define sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy 2 ) naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . 17 . Male patient must use effective barrier method contraception study 3 month follow last dose sexually active FCBP . 1 . Multiple Myeloma IgM subtype . 2 . Glucocorticoid therapy ( prednisone &gt; 30 mg/day equivalent ) within 14 day prior randomization . 3 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) . 4 . Plasma cell leukemia circulate plasma cell ≥ 2 × 10^9/L . 5 . Waldenstrom 's Macroglobulinemia . 6 . Patients know amyloidosis . 7 . Chemotherapy approve investigational anticancer therapeutic within 21 day prior randomization . 8 . Patients randomize previously randomize OnyxSponsored Phase 3 trial . 9 . Focal radiation therapy within 7 day prior randomization . Radiation therapy extend field involve significant volume bone marrow within 21 day prior randomization ( i.e. , prior radiation must less 30 % bone marrow ) . 10 . Immunotherapy within 21 day prior randomization . 11 . Major surgery ( exclude kyphoplasty ) within 28 day prior randomization . 12 . Active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention . Myocardial infarction within four month prior randomization . 13 . Acute active infection require systemic antibiotic , antiviral ( except antiviral therapy direct hepatitis B ) antifungal agent within 14 day prior randomization . 14 . Known human immunodeficiency ( HIV ) seropositive , hepatitis C infection , and/or hepatitis B ( except patient hepatitis B surface antigen [ SAg ] core antibody receive respond antiviral therapy direct hepatitis B : patient allow ) . 15 . Patients know cirrhosis . 16 . Second malignancy within past 3 year except : adequately treat basal cell squamous cell skin cancer carcinoma situ cervix prostate cancer &lt; Gleason score 6 stable prostatespecific antigen ( PSA ) 12 month breast carcinoma situ full surgical resection treat medullary papillary thyroid cancer 17 . Patients myelodysplastic syndrome . 18 . Significant neuropathy ( Grades 3 4 , Grade 2 pain ) within 14 day prior randomization . 19 . Female patient pregnant lactate . 20 . Known history allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) . 21 . Patients hypersensitivity carfilzomib , Velcade , boron , mannitol . 22 . Patients contraindication dexamethasone . 23 . Contraindication require concomitant drug supportive treatment , include hypersensitivity antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment . 24 . Ongoing graftvshost disease . 25 . Patients pleural effusion require thoracentesis ascites require paracentesis within 14 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>relapse multiple myeloma</keyword>
</DOC>